Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

US pharma major AbbVie has posted financial results for the fourth quarter and full year ended December 31, 2024, that pleased investors and sending the firm’s shares up 7.8% to $189.19 by mid-morning ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

UK pharma major AstraZeneca has scrapped its plans to invest £450 million in expanding ($559 million) to expand its vaccine plant in Speke, Liverpool, blaming a reduction in government support.

Blackstone (NYSE: BX), the world’s largest alternative asset manager, is expanding its presence in the life sciences sector ...

Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...

Rentschler Biopharma is moving away from cell and gene therapy as part of a strategic realignment, opting to focus more on ...

The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the USA as the first HER2-directed ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...